PRESIDENT OF BRENNTAG SPECIALTIES, AMERICAS– BRENNTAG NORTH AMERICA, INC
"Project Brenntag and our supply chain capabilities have certainly supported us, providing a clear focus between our different businesses and specializations to grow in the pharma and life science markets."
"The surge of communication need has increased exponentially as companies recognize the necessity of conveying a differentiated story amid the unprecedented number of financings and IPOs over the last two years."
"The M&A market has been relatively slow over the past year as pharma executives wait on the sidelines for the valuation correction to play out, but I believe that we will see M&A activities increase in this coming year."
"Nivagen has excellent connections and market access, and we are always looking to in-license FDA-approved products that leverage our expertise in launching in the US market."
"MassBio remains focused on providing the necessary support to help companies succeed so we can continue to stay the best place in the world for life sciences."
"The main trait we are looking for in partners is access to interesting chemical libraries where, combining good chemistry with our platforms, we can identify novel treatments for neuropsychiatric disorders."
"People are realizing that our sector may need to be more discerning in deciding which companies are worthy and mature enough to bring to the public markets."
"Through our growing network of cGMP facilities across Europe and the US, we aim to continue to translate complex processes and projects at any stage of development into high-value products."
Mexico's chemical industry faces challenges in securing a reliable feedstock supply and maintaining global competitiveness. A shift towards sustainable energy and local production could provide long-term growth opportunities, and some sectors are booming, including Mexico's dynamic chemical distribution market.